Cost comparisons of five leading brands of the antihypertensive drug, Telmisartan, available in an Indian city
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20192205Keywords:
Annual cost, Antihypertensives, Pharmacoeconomics, Temisartan 40 milligramAbstract
Background: Antihypertensive drugs have to be taken lifelong, after initiation of the treatment. Price variation can lead to huge economic burden on the patients of hypertension, especially when cost considerations are not undertaken by the prescribing physician . This study was undertaken to compare the annual cost , to the patient , of five different most commonly prescribed brands of Telmisartan 40 mg, in Kolhapur city.
Methods: Authors purchased a strip of 10 tablets each of the five leading brands in one city, Kolhapur, India, of Telmisartan 40 milligram. The prices of the strip of 10 tablets of each of the five selected brands were compared. In turn the annual cost of each of these five, was compared directly as well as using percentages. The data was collected, analysed and presented.
Results: The data of the cost of the preparations of five different brands of a single antihypertensive drug, Temisartan 40 milligram shows that the annual cost of the costliest among the three brands of this drug is almost three times , that of the cheapest brand, or in other words almost 300 percent that of the cheapest brand.
Conclusions: the cost variation amongst the five brands was considerable. India being a country with a major chunk of the population being very price sensitive, the prescribing physician must select the brand carefully. The most costly preparation of Temisartan can significantly add to the burden on the patient’s annual budget. Thus, Pharmacoeconomics must take an important place while prescribing medicines, especially in a country like India.
Metrics
References
Anchala R, Kannuri NK, Pant H, Khan H, Franco OH, Angelantonio ED, et al. Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. J Hypertens. 2014;32(6):1170-7.
Banerji A. Review of Asia-Pacific's healthcare systems with emphasis on the role of generic pharmaceuticals. Academy of Health Care Management J. 2013;9(1/2):53A.
Kotwani A, Ewen M, Dey D, Iyer S, Lakshmi PK, Patel A, et al. Prices and availability of common medicines at six sites in India using a standard methodology. Indian J Med Res. 2007;125(5):645-54.
DPCO, Drug Price Control Order 2013 - National Pharmaceutical Pricing Authority; 2013. Available at: http://www.arthapedia.in
Ahmad A, Patel I, Sanyal S, Balkrishnan R, Mohanta GP. Availability, cost and affordability of antimalarial medicines in India. Int J Pharm Clin Res. 2014;6(1):7-12.
Harvard School of Public Health, Boston, MA, USA. How Effective Is India's Drug Price Control Regime? 2007. Available at: https://cdn1.sph.harvard.edu/wp-content/uploads/sites/114/2012/10/RP256.pdf.
Sahay A, Jaikumar S. Does pharmaceutical price regulation result in greater access to essential medicines? Study of the impact of drug price control order on sales volume of drugs in India. Research and publication of Indian Institute of management, Ahmadabad. W.P.2016-02-01, Jan 2016;1-28.
DPCO Impact: Pharma cos growth suffers for drugs under price ceiling/ Business Standard News, 2013. Available at: https://www.business-standard.com/article/companies/dpco-impact-pharma-cos-growth-suffers-for-drugs-under-price-ceiling-113081800677_1.html.
Vernon, John A, Golec JH, and Hughen WK. The Economics of Pharmaceutical Price Regulation and Importation: Refocusing the Debate. Amer J Law Medi. 2006;32(2-3):175-92.
Balarajan Y, Selvaraj S, Subramanian SV. Health care and equity in India. Lancet. 2011;377(9764):505-15.
Downloads
Published
How to Cite
Issue
Section
